Mereo BioPharma Group (LTS:0A9G) Cash And Cash Equivalents : $62.48 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Mereo BioPharma Group Cash And Cash Equivalents?

Mereo BioPharma Group's quarterly cash and cash equivalents declined from Sep. 2024 ($80.52 Mil) to Dec. 2024 ($69.80 Mil) but then stayed the same from Dec. 2024 ($69.80 Mil) to Mar. 2025 ($62.48 Mil).

Mereo BioPharma Group's annual cash and cash equivalents declined from Dec. 2022 ($68.18 Mil) to Dec. 2023 ($57.42 Mil) but then increased from Dec. 2023 ($57.42 Mil) to Dec. 2024 ($69.80 Mil).

Mereo BioPharma Group Cash And Cash Equivalents Historical Data

The historical data trend for Mereo BioPharma Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Cash And Cash Equivalents Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

31.98

127.27

68.18

57.42

69.80

Mereo BioPharma Group Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															48.66	87.43	80.52	69.80	62.48

Mereo BioPharma Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Mereo BioPharma Group (LTS:0A9G) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Mereo BioPharma Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (LTS:0A9G) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

MREO:USA MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines